Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with various cardiometabolic risk factors, including insulin resistance, dyslipidemia, hypertension, and obesity, which contribute to an increased risk of cardiovascular diseases. This inaugural systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the impact of magnesium supplementation on various cardiometabolic risk factors and hormonal parameters in patients with polycystic ovary syndrome (PCOS). : We systematically searched the MEDLINE, Web of Science, Scopus, and Cochrane databases until 30 March 2024 for studies comparing magnesium supplementation to control in improving cardiometabolic and hormonal factors in PCOS patients. Endpoints were summarized as mean differences (MD) and 95% confidence intervals (CIs) in a random-effects model. : The primary search yielded 176 studies. After screening, six studies met our inclusion criteria. Our meta-analysis showed no significant effects of magnesium supplementation on cardiometabolic risk factors and hormonal parameters in patients with PCOS. : Magnesium supplementation does not appear to influence the cardiometabolic and hormonal factors in PCOS patients. Further rigorous RCTs are needed to strengthen the evidence and support comprehensive analysis in this area. PROSPERO database (CRD42024526110).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857371 | PMC |
| http://dx.doi.org/10.3390/medicina61020280 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
Feasibility and efficacy of exercise training on sleep symptoms and comorbidities in narcolepsy type 1: a prospective interventional study.
Sleep
September 2025
Center for Sleep Medicine, Hospices Civils de Lyon, Lyon 1 University, Lyon, F-69000, France.
Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program.
View Article and Find Full Text PDFAssociations of sleep duration and quality with risk of incident obesity, diabetes, and metabolic syndrome: Results from the Midlife in the United States study.
Chronobiol Int
September 2025
Consultant, Wayzek Science, St Paul, Minnesota, USA.
Understanding how sleep affects the risk of incident chronic conditions in midlife may reinforce the importance of a healthy sleep pattern for healthy aging and cardiometabolic health. The objective of the study was to examine associations of sleep duration and quality with incident obesity, diabetes and metabolic syndrome in mid-aged adults. Participants without obesity ( = 381), diabetes ( = 509), or metabolic syndrome ( = 487) from the Biomarker Projects in Midlife in the United States study were examined separately for baseline sleep duration and quality and their associations with incident obesity, diabetes, or metabolic syndrome after an average follow-up of 12 years.
View Article and Find Full Text PDFComposite endpoints in health technology assessment: Part 1 - an illustration of best modeling practice.
J Comp Eff Res
September 2025
British Heart Foundation, University of Glasgow, Glasgow, UK.
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory approval. However, employing composite endpoints introduces complexities into health technology assessments (HTAs), particularly in economic modeling, due to the varying clinical significance and cost implications of the components. In this paper, we explore best modeling practice for HTAs that are based on clinical trials that employ composite endpoints.
View Article and Find Full Text PDFModest psoriasis risk from cardiometabolic progression: Genetics, patterns and limitations in a Biobank study.
J Eur Acad Dermatol Venereol
September 2025
School of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.